ArticleTranslational cancer research2026
A disulfidptosis-related lncRNA prognostic model identifies MALINC1 as a regulator of platinum drug sensitivity in colon adenocarcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triggering tumor cell death still serves as the core and ultimate goal to restrict tumors including colorectal cancer, a highly lethal malignant alimentary canal tumor. Disulfidptosis, a newly defined form of programmed cell death, offers a new potential possibility for anti-tumor purposes. Studies have shown that long non-coding RNAs (lncRNAs) are involved in the regulation of tumor disulfidptosis, however, their role in colorectal cancer is yet poorly defined. In this study, we aim to explore the relationship between lncRNAs and disulfidptosis in colorectal cancer. Methods: We used RNA sequencing data of patients with colon adenocarcinoma (COAD) from The Cancer Genome Atlas (TCGA) to screen disulfidptosis-related lncRNAs via correlation analysis. Univariate, least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression algorithm were performed to identify key disulfidptosis-related lncRNAs and develop prognostic model. After each sample was labelled with risk score, Kaplan-Meier (KM) and receiver operating characteristic (ROC) curve analyses were conducted in both high risk-score and low risk-score groups. Additionally, quantitative polymerase chain reaction (qPCR) was used to assess expression pattern of key disulfidptosis-related lncRNAs in colon cancer cell lines. Cell Counting Kit-8 (CCK-8) assay, cell colony formation assay, cell counting assay were employed to investigate the roles of MALINC1 in colon cancer growth. Deeply, free thiol and glutathione (GSH) content assay and the protein level of disulfidptosis key player SLC7A11 were further implemented to study the relationship between MALINC1 and disulfidptosis. Furthermore, the effect of MALINC1 on the sensitivity of COAD cell lines to platinum-based drugs by CCK-8 assay, cell colony formation assay and cell counting assay. Results: We identified six key disulfidptosis-related lncRNAs, AL354993.2, AP003555.1, MALINC1, AC013652.1, AC074212.1 and AC007128.1. The prognostic model we developed successfully predict survival of patients with COAD. One of the six key disulfidptosis-related lncRNAs, MALINC1, is highly expressed in COAD cell lines HCT8 and SW480. Knockdown of MALINC1 markedly suppressed cell proliferation, reduced intracellular free sulfhydryl groups and GSH, and upregulated SLC7A11. Moreover, MALINC1 knockdown enhanced the sensitivity of these cells to platinum-based drugs. Conclusions: These findings suggest that a prognostic model based on six key disulfidptosis-related lncRNAs holds potential for predicting outcomes in patients with COAD, and that targeting MALINC1 may offer new insights into colorectal cancer chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.